▲ +142.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Equillium in the last 3 months. The average price target is $14.00, with a high forecast of $16.00 and a low forecast of $12.00. The average price target represents a 142.21% upside from the last price of $5.78.
The current consensus among 5 contributing investment analysts is to buy stock in Equillium. This Buy consensus rating has held steady for over two years.
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.